AIMS/HYPOTHESIS: Islet amyloid, formed by aggregation of human islet amyloid polypeptide (hIAPP), is associated with beta cell death in type 2 diabetes as well as in cultured and transplanted human islets. Impaired prohIAPP processing due to beta cell dysfunction is implicated in hIAPP aggregation. We examined whether the glucagon-like peptide-1 receptor (GLP-1R) agonist exenatide can restore impaired prohIAPP processing and reduce hIAPP aggregation in cultured human islets and preserve beta cell function/mass during culture conditions used in clinical islet transplantation. METHODS: Isolated human islets (n = 10 donors) were cultured with or without exenatide in normal or elevated glucose for 2 or 7 days. Beta cell apoptosis, proliferation, mass, function, cJUN N-terminal kinase (JNK) and protein kinase B (PKB) activation and amyloid formation were assessed. ProhIAPP, its intermediates and mature hIAPP were detected. RESULTS: Exenatide-treated islets had markedly lower JNK and caspase-3 activation and beta cell apoptosis, resulting in higher beta/alpha cell ratio and beta cell area than non-treated cultured islets. Exenatide improved beta cell function, manifested as higher insulin response to glucose and insulin content, compared with non-treated cultured islets. Phospho-PKB immunoreactivity was detectable in exenatide-treated but not untreated cultured islets. Islet culture caused impaired prohIAPP processing with decreased mature hIAPP and increased NH(2)-terminally unprocessed prohIAPP levels resulting in higher release of immature hIAPP. Exenatide restored prohIAPP processing and reduced hIAPP aggregation in cultured islets. CONCLUSIONS/ INTERPRETATION: Exenatide treatment enhances survival and function of cultured human islets and restores impaired prohIAPP processing in normal and elevated glucose conditions thereby reducing hIAPP aggregation. GLP-1R agonists may preserve beta cells in conditions associated with islet amyloid formation.
AIMS/HYPOTHESIS: Islet amyloid, formed by aggregation of human islet amyloid polypeptide (hIAPP), is associated with beta cell death in type 2 diabetes as well as in cultured and transplanted human islets. Impaired prohIAPP processing due to beta cell dysfunction is implicated in hIAPP aggregation. We examined whether the glucagon-like peptide-1 receptor (GLP-1R) agonist exenatide can restore impaired prohIAPP processing and reduce hIAPP aggregation in cultured human islets and preserve beta cell function/mass during culture conditions used in clinical islet transplantation. METHODS: Isolated human islets (n = 10 donors) were cultured with or without exenatide in normal or elevated glucose for 2 or 7 days. Beta cell apoptosis, proliferation, mass, function, cJUN N-terminal kinase (JNK) and protein kinase B (PKB) activation and amyloid formation were assessed. ProhIAPP, its intermediates and mature hIAPP were detected. RESULTS:Exenatide-treated islets had markedly lower JNK and caspase-3 activation and beta cell apoptosis, resulting in higher beta/alpha cell ratio and beta cell area than non-treated cultured islets. Exenatide improved beta cell function, manifested as higher insulin response to glucose and insulin content, compared with non-treated cultured islets. Phospho-PKB immunoreactivity was detectable in exenatide-treated but not untreated cultured islets. Islet culture caused impaired prohIAPP processing with decreased mature hIAPP and increased NH(2)-terminally unprocessed prohIAPP levels resulting in higher release of immature hIAPP. Exenatide restored prohIAPP processing and reduced hIAPP aggregation in cultured islets. CONCLUSIONS/ INTERPRETATION:Exenatide treatment enhances survival and function of cultured human islets and restores impaired prohIAPP processing in normal and elevated glucose conditions thereby reducing hIAPP aggregation. GLP-1R agonists may preserve beta cells in conditions associated with islet amyloid formation.
Authors: Clara Westwell-Roper; Derek L Dai; Galina Soukhatcheva; Kathryn J Potter; Nico van Rooijen; Jan A Ehses; C Bruce Verchere Journal: J Immunol Date: 2011-08-03 Impact factor: 5.422
Authors: K J Potter; A Abedini; P Marek; A M Klimek; S Butterworth; M Driscoll; R Baker; M R Nilsson; G L Warnock; J Oberholzer; S Bertera; M Trucco; G S Korbutt; P E Fraser; D P Raleigh; C B Verchere Journal: Proc Natl Acad Sci U S A Date: 2010-02-16 Impact factor: 11.205
Authors: S Zraika; R L Hull; J Udayasankar; K Aston-Mourney; S L Subramanian; R Kisilevsky; W A Szarek; S E Kahn Journal: Diabetologia Date: 2009-01-16 Impact factor: 10.122
Authors: Safia Costes; Chang-jiang Huang; Tatyana Gurlo; Marie Daval; Aleksey V Matveyenko; Robert A Rizza; Alexandra E Butler; Peter C Butler Journal: Diabetes Date: 2010-10-27 Impact factor: 9.461
Authors: Lucy Marzban; Alejandra Tomas; Thomas C Becker; Lawrence Rosenberg; Jose Oberholzer; Paul E Fraser; Philippe A Halban; C Bruce Verchere Journal: Diabetes Date: 2008-08-11 Impact factor: 9.461
Authors: Kathryn Aston-Mourney; Shoba L Subramanian; Sakeneh Zraika; Thanya Samarasekera; Daniel T Meier; Lynn C Goldstein; Rebecca L Hull Journal: Am J Physiol Endocrinol Metab Date: 2013-06-04 Impact factor: 4.310